Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) COO Sells 8,370 Shares of Stock

Posted by Brenda Bartman on Oct 6th, 2026

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) COO Jennifer Bush sold 8,370 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $6.84, for a total transaction of $57,250.80. Following the completion of the transaction, the chief operating officer directly owned 366,159 shares of the company’s stock, valued at approximately $2,504,527.56. The trade was a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Price Performance

ARTV traded up $0.14 on Tuesday, hitting $7.27. The company had a trading volume of 664,480 shares, compared to its average volume of 393,650. Artiva Biotherapeutics, Inc. has a 52-week low of $2.71 and a 52-week high of $14.53. The stock has a fifty day simple moving average of $10.09 and a 200-day simple moving average of $9.22. The firm has a market capitalization of $355.43 million, a P/E ratio of -2.20 and a beta of 2.40.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.63). Equities research analysts expect that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARTV has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating on shares of Artiva Biotherapeutics in a report on Friday. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 target price on shares of Artiva Biotherapeutics in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Artiva Biotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

View Our Latest Stock Report on ARTV

Institutional Investors Weigh In On Artiva Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. 5AM Venture Management LLC purchased a new position in Artiva Biotherapeutics in the 2nd quarter worth approximately $22,827,049. Blue Owl Capital Holdings LP purchased a new stake in Artiva Biotherapeutics during the 2nd quarter valued at $8,483,000. BlackRock Inc. purchased a new stake in Artiva Biotherapeutics during the 2nd quarter valued at $6,739,000. Nantahala Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth $2,910,000. Finally, Alyeska Investment Group L.P. raised its stake in shares of Artiva Biotherapeutics by 173.6% in the second quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after purchasing an additional 173,615 shares during the last quarter.

Artiva Biotherapeutics Company Profile

(Get Free Report)

Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.

Artiva’s lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.